| Autor: |
Heerspink HJ; Department of Clinical Pharmacy and Pharmacology, University of Groningen, 9700 RB Groningen, Netherlands; The George Institute for Global Health, Sydney, NSW, Australia. Electronic address: h.j.lambers.heerspink@umcg.nl., Cherney DZ; University of Toronto, ON, Canada., Groop PH; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia., Matthieu C; Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Tuttle KR; Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Kidney Research Institute and Institute of Translational Health Sciences, University of Washington, Seattle, WA, USA., McGill JB; Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO, USA. |
| Abstrakt: |
Competing Interests: HJLH received honoraria (to employer) for consultancy from AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Chinook, Dimerix, Eli Lilly, Gilead, Janssen R&D, Merck, Novartis, NovoNordisk, and Travere Therapeutics, and received a research grant from the Juvenile Diabetes Research Foundation (JDRF) to conduct clinical trials in individuals with type 1 diabetes and chronic kidney disease. DZIC received honoraria from Boehringer Ingelheim–Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, and Novo-Nordisk; received operational funding for clinical trials from Boehringer Ingelheim–Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk; is supported by a University of Toronto Merit Award from the Department of Medicine, the Canadian Institutes of Health Research, Diabetes Canada, and the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research. DZIC received a five-year Canadian Institutes of Health Research–Kidney Foundation of Canada Team Grant award. P-HG received honoraria for consultancy and lectures from AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Medscape, MSD, Mundipharma, Novo Nordisk, and Sanofi; and is supported by the Folkhälsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Life and Health Medical Fund, the Sigrid Jusélius Foundation, the Finnish Diabetes Research Foundation, the Finnish Foundation for Cardiovascular Research, the Medical Society of Finland, the Academy of Finland (316664), and by an NIDDK R01 grant (623 DK105154). CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd, Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz, and Vertex. Financial compensation for these activities was received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Imcyse, Novo Nordisk, Sanofi, and ActoBio Therapeutics. CM serves or has served on the speaker's bureau for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Novartis. Financial compensation for these activities has been received by KU Leuven. CM is President of the European Association for the Study of Diabetes, and all external support is to be found on their website. PR has received research support and honoraria (to institution) from AstraZeneca, Bayer, and Novo Nordisk, and honoraria (to institution) from Astellas, Abbott, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, and Sanofi. KRT reports consultancy for Eli Lilly, Boehringer Ingelheim, and AstraZeneca; consultancy and grants from Bayer; consultancy and speaker fees for Novo Nordisk; grants from Travere outside the submitted work; is supported by National Institutes of Health (NIH) research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, and Centres for Disease Control and Prevention contract 75D301-21-P-12254, and received a research grant from the JDRF to conduct a clinical trial in patients with type 1 diabetes and chronic kidney disease. JBM received honoraria from Bayer, Boehringer Ingelheim, Eli Lilly Mannkind, Novo Nordisk, Provention Bio, and Thermo Fisher; grant funding to the university from JDRF, NIH, and Novo Nordisk; is supported by grants from NIH and JDRF for clinical investigation unrelated to chronic kidney disease, and Novo Nordisk for a chronic kidney disease clinical trial. Editorial support in creating the figure was provided by Josh Abbott, BSc, and Moamen Hammad, PhD, both of Scion, London, UK, and supported by Bayer AG according to Good Publication Practice guidelines. |
